TRPC6 and pulmonary arterial hypertension: Recently, Jain et al. demonstrated that oral gavage with TRPC6 blocker BI-749237 reduced the development of PH induced by CH exposure in mice [191], suggesting that TRPC6 could be a potential target in PAH.